Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin.
OBJECTIVE
To study the disposition of single doses of phenytoin and itraconazole when administered alone and after chronic treatment with the other drug.


METHODS
Healthy male volunteers were randomized to two groups and studied in parallel. In group 1, a single 200 mg oral dose of itraconazole was administered on two occasions (alone and after 15 days of 300 mg oral phenytoin once daily). Subjects in group 2 were given a single 300 mg oral dose of phenytoin before and after 15 days of itraconazole (200 mg once daily). Blood was collected for 96 hours after each single dose of phenytoin or itraconazole. Serum was assayed for itraconazole and hydroxyitraconazole concentration by HPLC and for phenytoin concentration by fluorescence polarization immunoassay.


RESULTS
Phenytoin decreased the area under the concentration-time curve (AUC) of itraconazole by more than 90%, from 3203 to 224 ng.hr/ml, accompanied by a decrease in half-life from 22.3 to 3.8 hours. Similar changes were observed for hydroxyitraconazole AUC (decreased from 6224 to 315 ng.hr/ml) and half-life (11.3 versus 2.9 hours). Itraconazole increased the AUC of phenytoin (10.3%; p < 0.05), with no change in any other pharmacokinetic parameter.


CONCLUSIONS
The striking decrease in itraconazole concentrations with phenytoin is due to induction of metabolism combined with a reduction in the degree of saturable metabolism normally exhibited by itraconazole at this dose. The magnitude of interaction likely accounts for reports of therapeutic failures in patients with fungal infections who are receiving both itraconazole and phenytoin.
College of Pharmacy and Allied Health Professions, School of Medicine, Wayne State University, Detroit, MI 48202, USA.
M P
MP
Ducharme
R L
RL
Slaughter
L H
LH
Warbasse
P H
PH
Chandrasekar
V
V
Van de Velde
G
G
Mannens
D J
DJ
Edwards
D000328:Adult; D000704:Analysis of Variance; D000927:Anticonvulsants / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D000935:Antifungal Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D002851:Chromatography, High Pressure Liquid; D005453:Fluorescence; D006207:Half-Life; D006801:Humans; D007118:Immunoassay / Q000379:methods; D017964:Itraconazole / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000493:pharmacokinetics*; D008297:Male; D010672:Phenytoin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D012016:Reference Values
D000927:Anticonvulsants; D000935:Antifungal Agents; C084794:hydroxyitraconazole; D017964:Itraconazole; D010672:Phenytoin